Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/gutjnl-2018-317839 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with : a competing risks analysis provides a full picture of possible treatment effects.
Gut
February 2020
Faculty of Medicine and Medical Center, Institute for Medical Biometry and Statistics, University of Freiburg, Freiburg, Germany.
Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with (RAPID): a randomised placebo controlled trial.
Gut
July 2019
Nottingham Digestive Diseases Centre and NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals NHS Trust, the University of Nottingham, Nottingham, Notts, UK.
Background: Clostridium difficile infection (CDI) recurs after initial treatment in approximately one in four patients. A single-centre pilot study suggested that this could be reduced using 'follow-on' rifaximin treatment. We aimed to assess the efficacy of rifaximin treatment in preventing recurrence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!